Trials / Completed
CompletedNCT05939284
Progesterone-Primed Ovarian Simulation in Controlled-ovarian Simulation of Infertile PCOS Patients
Progesterone-Primed Ovarian Stimulation Might be a Safe and Effective Alternative to GnRH-antagonist Protocol for Controlled-Ovarian Stimulation of Infertile PCOS Women
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 238 (actual)
- Sponsor
- Zagazig University · Other Government
- Sex
- Female
- Age
- 20 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
The study evaluated the safety and efficacy of the progesterone-primed ovarian stimulation (PPOS) coupled with gonadotropin (FSH) for infertile women with polycystic ovary syndrome (PCOS) who were assigned for ICSI and frozen blastocyst transfer. 200 infertile women were divided randomly into Group C, which received Cetrorelix injection (0.25 mg daily) on day-6, and Group S, which received oral dydrogesterone (20 mg/day) on day-2 of the menstrual cycle till the trigger day. All patients received an FSH injection of 225 IU daily from day-2 till triggering day. ICSI was performed and day-5 blastocysts underwent vitrification ultra-rapid cryopreservation till being transferred. Outcomes included the ability of PPOS to suppress the premature luteinizing hormone (LH) surge and prevent the development of ovarian hyperstimulation syndrome (OHSS), the incidence of profound LH suppression, the number of retrieved M2 oocyte and fertilization, chemical and clinical pregnancy rates, and the miscarriage rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Injection of Cetrorelix | Patients received Cetrorelix subcutaneous injection on the day-6 in a dose of 0.25 daily till the trigger day. |
| DRUG | Oral insertion of dydrogeserone | Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2022-09-14
- Completion
- 2023-01-25
- First posted
- 2023-07-11
- Last updated
- 2023-07-11
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05939284. Inclusion in this directory is not an endorsement.